Compare

ADMA Biologics, Inc. vs Twist Bioscience Corp vs Immunocore Holdings plc vs Repligen Corp

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearADMA Biologics, Inc.
ADMA
Twist Bioscience Corp
TWST
Immunocore Holdings plc
IMCR
Repligen Corp
RGEN
Year ended2025-12-312026-09-302025-12-312025-12-31
Revenue$510.17M$459.43M$400.02M$738.26M
Revenue growth (YoY)+19.6%+22.0%+29.0%+16.4%
Gross margin57.4%52.4% (computed)n/a52.3% (computed)
Operating margin37.5%-30.4%-11.3%7.5%
Net margin28.8%-28.3%-8.9%6.6%
Net income$146.93M-$130.20M-$35.51M$48.89M
EPS (Diluted)$0.60-$2.08-$0.71$0.86
Operating cash flow$50.40M-$41.43M-$10.71M$117.42M
Free cash flow$27.82M-$89.01M-$15.05M$93.90M
Cash & equivalents$87.63M$533.99M$467.71M$566.02M
Total assets$624.24M$1.12B$1.07B$2.95B
Total liabilities$146.92M$233.79M$686.24M$843.57M
Shareholders' equity$477.32M$888.02M$381.03M$2.11B
Return on year-end equity30.8%-14.7%-9.3%2.3%
Shares outstanding237.87M67.81M50.69M56.33M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearADMA Biologics, Inc.Twist Bioscience CorpImmunocore Holdings plcRepligen Corp
Latest$510.17M
Ended 2025-12-31
$459.43M
Ended 2026-09-30
$400.02M
Ended 2025-12-31
$738.26M
Ended 2025-12-31
1 year earlier$426.45M
Ended 2024-12-31
$376.57M
Ended 2025-09-30
$310.20M
Ended 2024-12-31
$634.44M
Ended 2024-12-31
2 years earlier$258.21M
Ended 2023-12-31
$312.97M
Ended 2024-09-30
$249.43M
Ended 2023-12-31
$632.36M
Ended 2023-12-31
3 years earlier$154.08M
Ended 2022-12-31
$245.11M
Ended 2023-09-30
$174.36M
Ended 2022-12-31
$801.54M
Ended 2022-12-31
4 years earlier$80.94M
Ended 2021-12-31
$203.56M
Ended 2022-09-30
$36.48M
Ended 2021-12-31
$670.53M
Ended 2021-12-31